Axsome Therapeutics, Inc. (AXSM)
AXSM Stock Price Chart
Explore Axsome Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze AXSM price movements and trends.
AXSM Company Profile
Discover essential business fundamentals and corporate details for Axsome Therapeutics, Inc. (AXSM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Nov 2015
Employees
712.00
Website
https://www.axsome.comCEO
Herriot Tabuteau
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
AXSM Financial Timeline
Browse a chronological timeline of Axsome Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 16 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.76.
Earnings released on 4 Aug 2025
EPS came in at -$0.92 surpassing the estimated -$1.00 by +8.00%, while revenue for the quarter reached $150.04M , beating expectations by +7.16%.
Earnings released on 5 May 2025
EPS came in at -$0.80 surpassing the estimated -$1.26 by +36.51%, while revenue for the quarter reached $121.46M , missing expectations by -13.51%.
Earnings released on 18 Feb 2025
EPS came in at -$0.96 surpassing the estimated -$1.00 by +4.00%, while revenue for the quarter reached $118.77M , missing expectations by -0.62%.
Earnings released on 12 Nov 2024
EPS came in at -$1.34 surpassing the estimated -$1.38 by +2.90%, while revenue for the quarter reached $104.76M , beating expectations by +6.50%.
Earnings released on 5 Aug 2024
EPS came in at -$1.24 surpassing the estimated -$1.30 by +4.62%, while revenue for the quarter reached $87.17M , beating expectations by +0.28%.
Earnings released on 6 May 2024
EPS came in at -$1.09 surpassing the estimated -$1.20 by +9.17%, while revenue for the quarter reached $75.00M , missing expectations by -13.46%.
Earnings released on 20 Feb 2024
EPS came in at -$0.73 surpassing the estimated -$1.21 by +39.67%, while revenue for the quarter reached $71.53M , beating expectations by +5.88%.
Earnings released on 6 Nov 2023
EPS came in at -$1.32 falling short of the estimated -$1.24 by -6.45%, while revenue for the quarter reached $57.79M , beating expectations by +3.67%.
Earnings released on 7 Aug 2023
EPS came in at -$1.00 surpassing the estimated -$1.24 by +19.35%, while revenue for the quarter reached $46.70M , beating expectations by +14.10%.
Earnings released on 8 May 2023
EPS came in at -$0.22 surpassing the estimated -$1.13 by +80.53%, while revenue for the quarter reached $94.58M , beating expectations by +255.28%.
Earnings released on 27 Feb 2023
EPS came in at -$1.28 falling short of the estimated -$1.18 by -8.47%, while revenue for the quarter reached $24.37M , beating expectations by +12.03%.
Earnings released on 7 Nov 2022
EPS came in at -$1.03 surpassing the estimated -$1.10 by +6.36%, while revenue for the quarter reached $16.85M , beating expectations by +1.26%.
Earnings released on 9 Aug 2022
EPS came in at -$1.06 surpassing the estimated -$1.19 by +10.92%, while revenue for the quarter reached $8.82M , beating expectations by +27.49%.
Earnings released on 2 May 2022
EPS came in at -$1.03 falling short of the estimated -$1.02 by -0.98%.
Earnings released on 1 Mar 2022
EPS came in at -$0.90 surpassing the estimated -$0.99 by +9.09%.
Earnings released on 8 Nov 2021
EPS came in at -$0.93 surpassing the estimated -$0.94 by +1.06%.
Earnings released on 9 Aug 2021
EPS came in at -$0.86 surpassing the estimated -$0.88 by +2.27%.
Earnings released on 10 May 2021
EPS came in at -$0.78 surpassing the estimated -$0.83 by +6.02%.
Earnings released on 1 Mar 2021
EPS came in at -$0.78 falling short of the estimated -$0.73 by -6.85%.
Earnings released on 5 Nov 2020
EPS came in at -$0.58 matching the estimated -$0.58.
AXSM Stock Performance
Access detailed AXSM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.